| Literature DB >> 21359647 |
Jan Bembenek1, Michal Karlinski, Adam Kobayashi, Anna Czlonkowska.
Abstract
Deep venous thrombosis (DVT) is a serious complication of various medical conditions including acute stroke. Our aim was to identify the occurrence of early stroke-related DVT, risk factors for its development and the influence on outcome. The study involved consecutive patients admitted to our center due to acute ischaemic (n = 278) or haemorrhagic (n = 12) stroke during a 16-month period. We collected data on their pre-stroke health status, neurological deficit on admission and baseline serum CRP and fibrinogen level. Ultrasonographic imaging was performed at the 3rd (IQR: 2-4) and 9th (IQR: 8-9) day after stroke. Patients thrombosis occurring between the first and second examination comprised the newly developed early stroke-related DVT group. We found DVT in 8.0% (24/299) of patients at initial evaluation. Newly developed DVT was present in 3.0% (9/299) of patients, and was predominantly distal (7 of 9 cases). It was associated with elevated serum CRP level (OR 8.75; 95%CI: 1.61-47.6), which was verified in a model adjusted for stroke severity and pre-stroke dependency (3-5 pts. in mRS). In a multivariate model, newly developed DVT significantly increased the risk of 3-month mortality (OR 12.4; 95%CI: 1.72-89.4), without affecting the combined risk of dependency and death (OR 2.57; 95%CI: 0.39-17.0). Early stroke-related DVT is an infrequent complication. However, it may be an independent risk factor for 3-month mortality. Increased serum CRP level combined with normal fibrinogen level seems predictive for development of DVT. It may be reasonable to provide those patients with additional DVT prophylaxis.Entities:
Mesh:
Year: 2011 PMID: 21359647 PMCID: PMC3111553 DOI: 10.1007/s11239-010-0548-3
Source DB: PubMed Journal: J Thromb Thrombolysis ISSN: 0929-5305 Impact factor: 2.300
Comparison of the study group and patients not included in the study
| Not included | Included |
| |||
|---|---|---|---|---|---|
| N | Observed (%) | N | Observed (%) | ||
| Age (median, IQR) | 126 | 72 (62–81) | 299 | 75 (64–82) | 0.162 |
| Female sex | 126 | 62 (49.2%) | 299 | 159 (53.2%) | 0.454 |
| Arterial hypertension | 126 | 89 (70.6%) | 288 | 214 (74.3%) | 0.438 |
| Congestive heart failure | 123 | 32 (26.0%) | 290 | 72 (24.8%) | 0.799 |
| Atrial fibrillation | 123 | 30 (24.4%) | 290 | 61 (21.0%) | 0.452 |
| Diabetes | 124 | 16 (12.9%) | 297 | 54 (18.2%) | 0.185 |
| Smoking status | |||||
| Current smokers | 123 | 28 (22.8%) | 298 | 74 (24.8%) | 0.652 |
| Past smokers | 122 | 55 (45.1%) | 296 | 140 (47.3%) | 0.680 |
| Oral anticoagulants | 125 | 14 (11.2%) | 296 | 21 (7.1%) | 0.163 |
| Pre-stroke disability | |||||
| mRS 0–1 pt. | 126 | 85 (67.5%) | 299 | 218 (72.9%) | 0.257 |
| mRS 0–2 pts. | 126 | 95 (75.4%) | 299 | 246 (82.3%) | 0.104 |
| Stroke severity (median, IQR%) | 126 | 8 (3–20) | 299 | 5 (2–9) | <0.001 |
| NIHSS ≤7 pts. | 126 | 59 (46.8%) | 299 | 205 (68.6%) | <0.001 |
| NIHSS 8–14 pts. | 126 | 20 (15.9%) | 299 | 52 (17.4%) | 0.703 |
| NIHSS >14 pts. | 126 | 47 (37.3%) | 299 | 42 (14.0%) | <0.001 |
| Decreased consciousness | |||||
| Not present | 126 | 78 (61.9%) | 299 | 256 (85.6%) | <0.001 |
| 1 pt. in NIHSS | 126 | 24 (19.0%) | 299 | 30 (10.0%) | 0.011 |
| ≥2 pts. in NIHSS | 126 | 24 (19.0%) | 299 | 13 (4.3%) | <0.001 |
Baseline characteristics of the study population and 3-month outcomes
| Newly developed DVT group | Old DVT or non-DVT group |
| |||
|---|---|---|---|---|---|
| N | Observed (%) | N | Observed (%) | ||
| Age (median, IQR) | 9 | 68.0 (63–79) | 290 | 75 (65–82) | 0.429 |
| Female sex | 9 | 5 (55.6%) | 290 | 154 (53.1%) | 1.000 |
| Arterial hypertension | 9 | 7 (77.8%) | 279 | 207 (74.2%) | 1.000 |
| Congestive heart failure | 9 | 4 (44.4%) | 281 | 68 (24.2%) | 0.233 |
| Atrial fibrillation | 9 | 2 (22.2%) | 281 | 59 (21.0%) | 1.000 |
| Diabetes | 9 | 3 (33.3%) | 288 | 51 (17.7%) | 0.213 |
| Smoking status | |||||
| Current smokers | 9 | 2 (22.2%) | 289 | 72 (24.9%) | 1.000 |
| Past smokers | 9 | 4 (44.4%) | 287 | 136 (47.4%) | 1.000 |
| Oral anticoagulants | 9 | 0 (0%) | 287 | 21 (7.3%) | 1.000 |
| Pre-stroke disability | |||||
| mRS 0–1 pt. | 9 | 6 (66.7%) | 290 | 222 (74.1%) | 0.707 |
| mRS 0–2 pts. | 9 | 8 (88.9%) | 290 | 238 (82.1%) | 1.000 |
| Ischaemic stroke | 9 | 9 (100.0%) | 290 | 269 (92.8%) | 1.000 |
| Stroke severity [median, IQR] | 9 | 8 (4–20.5) | 290 | 5 (2–9) | 0.090 |
| NIHSS ≤7 pts. | 9 | 4 (44.4%) | 290 | 201 (69.3%) | 0.146 |
| NIHSS 8–14 pts. | 9 | 3 (33.3%) | 290 | 49 (16.9%) | 0.193 |
| NIHSS >14 pts. | 9 | 2 (22.2%) | 290 | 40 (138%) | 0.368 |
| Decreased consciousness | |||||
| Not present | 9 | 6 (66.7%) | 290 | 250 (86.2%) | 0.125 |
| 1 pt. in NIHSS | 9 | 2 (22.2%) | 290 | 28 (9.7%) | 0.225 |
| ≥2 pts. in NIHSS | 9 | 1 (11.1%) | 290 | 12 (4.1%) | 0.333 |
| Inflammatory markers | |||||
| CRP >10 mg/dl | 9 | 7 (77.8%) | 276 | 90 (32.6%) | 0.008 |
| Fibrinogen >4 mg/dl | 9 | 4 (44.4%) | 276 | 203 (73.6%) | 0.067 |
| Fibrinogen [median, IQR] | 9 | 3.8 (3.4–5.8) | 276 | 4.7 (4.0–5.8) | 0.230 |
| Stroke outcome at 3 months | |||||
| Mortality | 7 | 3 (42.9%) | 275 | 27 (9.8%) | 0.028 |
| Death or dependency (mRS 3–6%) | 7 | 4 (57.1%) | 275 | 113 (41.1%) | 0.454 |
| Dependency in survivors (mRS 3–5%) | 4 | 1 (25.0%) | 248 | 86 (34.7%) | 1.000 |
Unadjusted and adjusted odds ratio for early stroke-related DVT
| Univariate model | Multivariate model* | |||||
|---|---|---|---|---|---|---|
| OR | 95%CI |
| OR | 95%CI |
| |
| Age (for each additional 10 years) | 0.91 | (0.70–1.19) | 0.507 | 0.64 | (0.33–1.23) | 0.176 |
| Female sex | 1.10 | (0.29–4.22) | 0.885 | 0.81 | (0.20–3.37) | 0.775 |
| Hypertension | 1.22 | (0.25–6.04) | 0.809 | 1.44 | (0.27–7.61) | 0.665 |
| Congestive heart failure | 2.51 | (0.65–9.65) | 0.180 | 1.71 | (0.41–7.05) | 0.458 |
| Atrial fibrillation | 1.08 | (0.22–5.34) | 0.929 | 0.65 | (0.12–3.48) | 0.609 |
| Diabetes | 2.32 | (0.56–9.65) | 0.244 | 4.16 | (0.84–20.6) | 0.079 |
| Smoking status | ||||||
| Current smoker | 0.86 | (0.17–4.37) | 0.854 | 1.59 | (0.28–8.89) | 0.599 |
| Previous smoker | 0.89 | (0.23–3.39) | 0.862 | 0.97 | (0.24–3.93) | 0.969 |
| Pre–stroke disability | 1.05 | (0.65–1.72) | 0.834 | 0.97 | (0.58–1.62) | 0.923 |
| mRS 0–1 pt. | 0.74 | (0.18–3.03) | 0.670 | 0.95 | (0.21–4.23) | 0.947 |
| mRS 0–2 pts. | 1.75 | (0.21–14.4) | 0.602 | 0.44 | (0.05–3.90) | 0.460 |
| Stroke severity | ||||||
| Each additional 4 pts. NIHSS | 1.30 | (0.96–1.75) | 0.083 | 1.21 | (0.86–1.69) | 0.271 |
| NIHSS >7 pts. | 2.82 | (0.74–10.8) | 0.129 | 2.11 | (0.50–8.96) | 0.307 |
| NIHSS >14 pts. | 1.79 | (0.35–8.96) | 0.479 | 1.34 | (0.25–7.30) | 0.732 |
| Decreased consciousness | ||||||
| ≥1 pt. in NIHSS | 3.13 | (0.75–13.1) | 0.117 | 2.09 | (0.46–9.54) | 0.337 |
| ≥2 pts. in NIHSS | 2.90 | (0.33–25.3) | 0.334 | 1.90 | (0.19–19.0) | 0.583 |
| Inflammatory markers | ||||||
| CRP >10 mg/l | 7.23 | (1.46–35.8) | 0.015 | 10.1 | (1.93–52.9) | 0.006 |
| Fibrinogen >4 mg/dl | 0.29 | (0.07–1.11) | 0.069 | 0.18 | (0.04–0.74) | 0.017 |
* Adjusted for elevated blood CRP level (>10 mg/dl) and fibrinogen level (>4 mg/dl)
Adjusted odds ratio for 3-month mortality and unfavorable outcome (mRS 2–6)
| Death at 3 months* | Death or dependencya | |||||
|---|---|---|---|---|---|---|
| OR | 95%CI |
| OR | 95%CI |
| |
| Newly developed DVT | 12.4 | (1.72–89.4) | 0.012 | 2.57 | (0.39–17.0) | 0.324 |
| Age (for each additional 10 years) | 2.05 | (1.17–3.59) | 0.011 | 1.55 | (1.14–2.10) | 0.005 |
| Oral anticoagulants | 5.58 | (1.11–28.1) | 0.036 | |||
| Pre-stroke nondisability (mRS 0–1) | 0.25 | (0.12–0.50) | <0.001 | |||
| Stroke severity (for each 4 NIHSS) | 1.78 | (1.36–2.31) | <0.001 | 2.79 | (2.08–3.74) | <0.001 |
| CRP > 10 mg/l | 2.94 | (1.08–7.96) | 0.034 | |||
* Model adjusted for all presented variables; a Model adjusted for all presented excluding newly developed DVT